Skip to content

Dynamic monitoring of peripheral T-cell lymphoma (PTCL) patients in China based on circulating tumor DNA

Dynamic monitoring of peripheral T-cell lymphoma (PTCL) patients in China based on circulating tumor DNA

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060450
Enrollment
Unknown
Registered
2022-06-01
Start date
2022-05-31
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral T-cell lymphoma (PTCL)

Interventions

case series:Nil

Sponsors

Harbin First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. According to the 2016 WHO classification of hematopoietic and lymphoid tumors, the histopathological diagnosis was confirmed as newly diagnosed PTCL patient; 2. Aged >=18 years; 3. The Eastern Cancer Collaboration (ECOG) Physical status score was 0-2; 4. Expected survival time of patients >=6 months; 5. The patient agrees to have the specimens submitted for genomic analysis; 6. CD30 expression was detected in patient tissue samples; 7. Patients need to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Previously or currently suffering from other hematologic malignancies; 2. Baseline samples are incomplete (tissue, peripheral blood, saliva) due to various reasons; 3. Patients with drug and chronic alcohol abuse that affect the evaluation of study results; 4. Patients who were judged unsuitable for this study by other researchers.

Design outcomes

Primary

MeasureTime frame
Complete Response;Partial Response;Stable Disease;Progressive Disease;

Countries

China

Contacts

Public ContactMa Jun
mjun0322@126.com+86 13304518000

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026